北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学深圳医院  > 期刊论文
学科主题: 临床医学
题名:
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis
作者: Li, Ting1,2; Zhu, Yuxia1,2; Fan, Shangrong1,3; Liu, Xiaoping4; Xu, Huicong4; Liang, Yiheng1
关键词: vulvovaginal candidiasis ; terconazole ; fluconazole
刊名: MEDICAL MYCOLOGY
发表日期: 2015-06-01
DOI: 10.1093/mmy/myv017
卷: 53, 期:5, 页:455-461
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Mycology ; Veterinary Sciences
研究领域[WOS]: Mycology ; Veterinary Sciences
关键词[WOS]: VULVOVAGINAL CANDIDIASIS ; BORIC-ACID ; SUSCEPTIBILITY ; CANDIDOSIS ; VAGINITIS ; GLABRATA ; GUIDELINES ; MANAGEMENT ; PATIENT ; YEASTS
英文摘要:

Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7-14 days and 30-35 days following the last dose of therapy. The clinical cure rates in the terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7-14 and 60.3% (35/58) and 56.1% (37/66) at day 30-35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7-14 and 62.1% (36/58) and 53.0% (35/66) at day 30-35 (P > .05 for all). Local irritation was the primary adverse event associated with terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150 mg) in the treatment of patients with SVVC; as such, terconazole could be a choice for therapy of this disorder.

语种: 英语
所属项目编号: 201201001 ; JCYJ 20140415162338813
项目资助者: Shenzhen Science and Technology
WOS记录号: WOS:000356249800004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58627
Appears in Collections:北京大学深圳医院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Shenzhen Hosp, Dept Obstet & Gynecol, Shenzhen 518036, Peoples R China
2.Shantou Univ, Coll Med, Shantou 515041, Guangdong, Peoples R China
3.Shenzhen Key Lab Gynecol Diagnost Technol Res, Shenzhen 518036, Peoples R China
4.Peking Univ, Shenzhen Hosp, Dept Lab Sci, Shenzhen 518036, Peoples R China

Recommended Citation:
Li, Ting,Zhu, Yuxia,Fan, Shangrong,et al. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis[J]. MEDICAL MYCOLOGY,2015,53(5):455-461.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Ting]'s Articles
[Zhu, Yuxia]'s Articles
[Fan, Shangrong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Ting]‘s Articles
[Zhu, Yuxia]‘s Articles
[Fan, Shangrong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace